AZD2693 explained

Drug Name:	AZD2693
Synonyms:	ION839
Legal Status:	Investigational
Cas Number:	2603457-19-6

AZD2693 is an antisense therapy developed by AstraZeneca for the treatment of non-alcoholic fatty liver disease based on the PNPLA3 gene, believed to be the largest single genetic risk factor for this condition.^{[1] [2] [3] [4]}

Notes and References

1. Dolgin . Elie . NASH therapies head toward landmark approval . Nature Biotechnology . 1 May 2023 . 41 . 5 . 587–590 . 10.1038/s41587-023-01787-8 . 37142707 . en . 1546-1696.
2. Cherubini . Alessandro . Casirati . Elia . Tomasi . Melissa . Valenti . Luca . PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date . Expert Opinion on Therapeutic Targets . 2 December 2021 . 25 . 12 . 1033–1043 . 10.1080/14728222.2021.2018418. 34904923 . 2434/889573 . free .
3. Sasso . Janet M. . Ambrose . Barbara J. B. . Tenchov . Rumiana . Datta . Ruchira S. . Basel . Matthew T. . DeLong . Robert K. . Zhou . Qiongqiong Angela . The Progress and Promise of RNA Medicine─An Arsenal of Targeted Treatments . Journal of Medicinal Chemistry . 26 May 2022 . 65 . 10 . 6975–7015 . 10.1021/acs.jmedchem.2c00024. 35533054 . 9115888 .
4. Pirola . Carlos J. . Sookoian . Silvia . PNPLA3 and COVID-19 outcomes: Thinking outside the box might explain the biology behind pleiotropic effects of rs738409 on the immune system . Liver International . November 2021 . 41 . 11 . 2801–2804 . 10.1111/liv.15043 . 1478-3223. free . 34455682 . 8662082 .